The All-Virtual 62nd Annual Society of Hematology Annual Meeting & Exposition is scheduled for December 2-11, 2020. The conference will feature research findings about many hematologic conditions, including chronic lymphocytic leukemia (CLL). Visit the ASH annual meeting website for more details.
Huge effort in the field of #PrecisionMedicine :
— Philippe Aftimos, MD (@aftimosp) June 11, 2021
🔹Molecular profiling 🧬of rare cancers
🔹Cross-institutional molecular tumor board👩💻👨💻(management recommendations, diagnostic reevaluation, genetic counseling, & experimental treatment)
🔹Treatment access💊and efficacy evaluation https://t.co/S66YtALeCu
Our paper on population diversity in cancer trials just out @IntJCanc
— emre yekeduz,MD (@yekeduz_emre) June 14, 2021
Honored to be included in this study w/ my great mentors @DrYukselUrun gungorutkan @DrChoueiri @curijoey @darioT_ @VriesElisabeth @ShuchiGulati @chadinabhan @VincentWenxinXu @oncology_bg @Chrislabaki1
At #EHA2021 good discussion on tailoring treatment in MM between @MyMKaiser and Dr. Stefania Oliva moderated by @Mohty_EBMT . 60% vs 40% for lag of evidence on tailoring, ie. predicting, #MultipleMyeloma treatment for now. @MDSAlliance @lyle_foreningen pic.twitter.com/BW9QPQgR6s
— MDS and You - MDS og Dig (@mds_niels) June 14, 2021
At #EHA2021 good discussion on tailoring treatment in MM between @MyMKaiser and Dr. Stefania Oliva moderated by @Mohty_EBMT . 60% vs 40% for lag of evidence on tailoring, ie. predicting, #MultipleMyeloma treatment for now. @MDSAlliance @lyle_foreningen pic.twitter.com/BW9QPQgR6s
— MDS and You - MDS og Dig (@mds_niels) June 14, 2021
Efficacy, safety, and surgical outcomes were summarized by @DoctorJSpicer, scientist in the RI-MUHC’s Cancer Research Program #CRP https://t.co/RmeUvC81b7
— RI-MUHC (@RIMUHC1) June 14, 2021
